Detail Infos ABP Brigatinib (exp. Arm) versus 2nd generation TKI (Alectinib or ceritinib, Standard arm)

Universitätsklinikum Freiburg ID: 475

• Entität NSCLC
• Therapie-Linie ED
• Altersgruppe ≥18
• Phase II
• Ein- / Auschlusskriterien - Histologically confirmed locally advanced (stage III) and not suitable for curative treatment, i.e. R0 operation or definitive chemo-/radiation, or metastatic (stage IV) ALK+ NSCLC - ECOG ≤ 2
• Arzt Prof. Dr. C. Waller: (cornelius.waller@uniklinik-freiburg.de)
• Study Nurse Nadja Singer: Telefon 0761/270 32914; (nadja.singer@uniklinik-freiburg.de)
• Link ClinicalTrials.gov